TW200411058A - Process for producing nerve cells - Google Patents
Process for producing nerve cells Download PDFInfo
- Publication number
- TW200411058A TW200411058A TW092117117A TW92117117A TW200411058A TW 200411058 A TW200411058 A TW 200411058A TW 092117117 A TW092117117 A TW 092117117A TW 92117117 A TW92117117 A TW 92117117A TW 200411058 A TW200411058 A TW 200411058A
- Authority
- TW
- Taiwan
- Prior art keywords
- cells
- cell
- stem cells
- medium
- scs
- Prior art date
Links
- 210000002569 neuron Anatomy 0.000 title claims abstract description 144
- 238000000034 method Methods 0.000 title claims abstract description 80
- 230000008569 process Effects 0.000 title abstract description 3
- 210000004027 cell Anatomy 0.000 claims abstract description 222
- 210000001671 embryonic stem cell Anatomy 0.000 claims abstract description 127
- 210000001130 astrocyte Anatomy 0.000 claims abstract description 109
- 239000000203 mixture Substances 0.000 claims abstract description 41
- 238000012258 culturing Methods 0.000 claims abstract description 30
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 210000001178 neural stem cell Anatomy 0.000 claims description 182
- 239000002609 medium Substances 0.000 claims description 145
- 238000004519 manufacturing process Methods 0.000 claims description 70
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 56
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 56
- 230000004069 differentiation Effects 0.000 claims description 51
- 239000001963 growth medium Substances 0.000 claims description 44
- 210000004498 neuroglial cell Anatomy 0.000 claims description 38
- 210000000130 stem cell Anatomy 0.000 claims description 26
- 239000000853 adhesive Substances 0.000 claims description 22
- 230000001070 adhesive effect Effects 0.000 claims description 21
- 241000282567 Macaca fascicularis Species 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 210000004500 stellate cell Anatomy 0.000 claims description 17
- 102000004190 Enzymes Human genes 0.000 claims description 15
- 108090000790 Enzymes Proteins 0.000 claims description 15
- 230000001617 migratory effect Effects 0.000 claims description 13
- 239000003102 growth factor Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 11
- 210000000653 nervous system Anatomy 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims description 9
- 230000008472 epithelial growth Effects 0.000 claims description 9
- 230000001537 neural effect Effects 0.000 claims description 9
- 102000004243 Tubulin Human genes 0.000 claims description 7
- 108090000704 Tubulin Proteins 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 230000024245 cell differentiation Effects 0.000 claims description 7
- 230000001413 cellular effect Effects 0.000 claims description 7
- 102000008763 Neurofilament Proteins Human genes 0.000 claims description 6
- 108010088373 Neurofilament Proteins Proteins 0.000 claims description 6
- 210000005044 neurofilament Anatomy 0.000 claims description 6
- 241000282414 Homo sapiens Species 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 claims 2
- 229940126864 fibroblast growth factor Drugs 0.000 claims 2
- 229920001661 Chitosan Polymers 0.000 claims 1
- 208000001848 dysentery Diseases 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 239000002689 soil Substances 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 abstract description 21
- 208000028389 Nerve injury Diseases 0.000 abstract description 16
- 230000008764 nerve damage Effects 0.000 abstract description 16
- 210000005036 nerve Anatomy 0.000 abstract description 15
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 11
- 230000008929 regeneration Effects 0.000 abstract description 3
- 238000011069 regeneration method Methods 0.000 abstract description 3
- 230000000626 neurodegenerative effect Effects 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 210000003061 neural cell Anatomy 0.000 description 66
- 238000004114 suspension culture Methods 0.000 description 62
- 102000008730 Nestin Human genes 0.000 description 43
- 108010088225 Nestin Proteins 0.000 description 43
- 210000005055 nestin Anatomy 0.000 description 43
- 238000003125 immunofluorescent labeling Methods 0.000 description 35
- 241000699666 Mus <mouse, genus> Species 0.000 description 30
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 24
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 21
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 19
- 229950004398 broxuridine Drugs 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 19
- 241000282693 Cercopithecidae Species 0.000 description 15
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 14
- 238000011835 investigation Methods 0.000 description 14
- 239000010410 layer Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 229960001231 choline Drugs 0.000 description 10
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 10
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 9
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 230000032823 cell division Effects 0.000 description 9
- 206010008118 cerebral infarction Diseases 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 8
- 208000026106 cerebrovascular disease Diseases 0.000 description 8
- 238000004264 monolayer culture Methods 0.000 description 8
- 210000002241 neurite Anatomy 0.000 description 8
- 208000020431 spinal cord injury Diseases 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 7
- 208000018737 Parkinson disease Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 238000004364 calculation method Methods 0.000 description 7
- 229960003638 dopamine Drugs 0.000 description 7
- 239000002344 surface layer Substances 0.000 description 7
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- 108090000489 Carboxy-Lyases Proteins 0.000 description 6
- 102000004031 Carboxy-Lyases Human genes 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 5
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 102000004357 Transferases Human genes 0.000 description 5
- 108090000992 Transferases Proteins 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000002858 neurotransmitter agent Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102100037362 Fibronectin Human genes 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- 230000004520 agglutination Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 101800000263 Acidic protein Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 230000003376 axonal effect Effects 0.000 description 3
- 210000001172 blastoderm Anatomy 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 210000005056 cell body Anatomy 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 description 2
- 241000486679 Antitype Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 2
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 239000012580 N-2 Supplement Substances 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 2
- 108010032788 PAX6 Transcription Factor Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 208000024777 Prion disease Diseases 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102100021380 Transcription factor GATA-4 Human genes 0.000 description 2
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 2
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001427 coherent effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000005016 dendritic process Effects 0.000 description 2
- 210000001900 endoderm Anatomy 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 230000002518 glial effect Effects 0.000 description 2
- 210000000020 growth cone Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 210000001259 mesencephalon Anatomy 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 230000035771 neuroregeneration Effects 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920005575 poly(amic acid) Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VUDQSRFCCHQIIU-UHFFFAOYSA-N 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C(Cl)=C(OC)C(Cl)=C1O VUDQSRFCCHQIIU-UHFFFAOYSA-N 0.000 description 1
- MXNRLFUSFKVQSK-UHFFFAOYSA-N 2-Amino-6-(trimethylazaniumyl)hexanoate Chemical compound C[N+](C)(C)CCCCC(N)C([O-])=O MXNRLFUSFKVQSK-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 1
- 102100033511 Keratin, type I cytoskeletal 17 Human genes 0.000 description 1
- 108010066325 Keratin-17 Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010048581 Lysine decarboxylase Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- -1 RC2 Proteins 0.000 description 1
- 102100034026 RNA-binding protein Musashi homolog 1 Human genes 0.000 description 1
- 101710129077 RNA-binding protein Musashi homolog 1 Proteins 0.000 description 1
- 208000011641 Spinocerebellar disease Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000794 anti-serotonin Effects 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000001159 caudate nucleus Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000004039 endoderm cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008508 epithelial proliferation Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 210000001704 mesoblast Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 230000003018 neuroregenerative effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002182386 | 2002-06-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200411058A true TW200411058A (en) | 2004-07-01 |
| TWI309678B TWI309678B (https=) | 2009-05-11 |
Family
ID=30112242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW092117117A TW200411058A (en) | 2002-06-24 | 2003-06-24 | Process for producing nerve cells |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8492145B2 (https=) |
| EP (1) | EP1516926A4 (https=) |
| JP (1) | JP4439396B2 (https=) |
| KR (1) | KR100846643B1 (https=) |
| CN (1) | CN1662645B (https=) |
| AU (1) | AU2003246176B2 (https=) |
| CA (1) | CA2489206C (https=) |
| IL (2) | IL165772A0 (https=) |
| TW (1) | TW200411058A (https=) |
| WO (1) | WO2004007700A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060183221A1 (en) * | 2003-03-31 | 2006-08-17 | Schulz Thomas C | Method for neural differentiation of embryonic stem cells using protease passaging techniques |
| WO2004099395A2 (en) * | 2003-05-08 | 2004-11-18 | Cellartis Ab | A method for the generation of neural progenitor cells |
| US7820439B2 (en) * | 2003-09-03 | 2010-10-26 | Reliance Life Sciences Pvt Ltd. | In vitro generation of GABAergic neurons from pluripotent stem cells |
| JP4481706B2 (ja) * | 2004-03-31 | 2010-06-16 | 独立行政法人科学技術振興機構 | 脳梗塞疾患モデルマウス |
| TW200617165A (en) * | 2004-09-06 | 2006-06-01 | Tanabe Seiyaku Co | Process for preparing a conditioned medium of astrocyte-like cells |
| US7803364B2 (en) | 2005-11-17 | 2010-09-28 | The Cleveland Clinic Foundation | Multipotent neural stem cells |
| JP5279491B2 (ja) * | 2006-05-19 | 2013-09-04 | 愛知県 | 脳損傷改善剤 |
| DE102006060247A1 (de) * | 2006-09-15 | 2008-03-27 | Ossacur Ag | Differenzierung von Stammzellen |
| WO2008066630A2 (en) * | 2006-10-27 | 2008-06-05 | Caritas St. Elizabeth Medical Center Of Boston, Inc. | Methods for reprogramming adult somatic cells and uses thereof |
| US8338176B2 (en) * | 2007-07-30 | 2012-12-25 | The Board Of Trustees Of The Leland Stanford Junior University | Derivation of neural stem cells from embryonic stem cells |
| DE102007036334A1 (de) * | 2007-08-02 | 2009-02-05 | Electrolux Home Products Corporation N.V. | Basiseinheit zum induktiven Aufheizen und Induktionsflüssigkeitserhitzungssystem |
| US20100021437A1 (en) * | 2008-04-07 | 2010-01-28 | The McLean Hospital Corporation Whitehead Institute for Biomedical Research | Neural stem cells derived from induced pluripotent stem cells |
| GB2460552B (en) * | 2008-06-05 | 2011-09-07 | Iti Scotland Ltd | Stem cell culture media and methods |
| JP5734595B2 (ja) * | 2010-08-03 | 2015-06-17 | オリンパス株式会社 | コロニーの特性評価方法 |
| BR112013003031A2 (pt) * | 2010-08-19 | 2016-06-14 | Hoffmann La Roche | método de produção de células hastes neurais (chn), células hastes neurais e seu uso, composição terapêutica e banco biológico de nscs |
| KR101226702B1 (ko) * | 2010-10-08 | 2013-01-25 | 충북대학교 산학협력단 | 인간 콜린 아세틸트랜스퍼라아제를 발현하는 인간 신경줄기세포 및 이의 용도 |
| TWI488641B (zh) * | 2010-12-13 | 2015-06-21 | 生化學工業股份有限公司 | 椎間盤突出治療劑 |
| KR20140121317A (ko) * | 2013-04-06 | 2014-10-15 | 서울대학교산학협력단 | 비신경 세포로부터 유도 신경 줄기 세포의 생산 방법 및 이에 의하여 생산되는 유도 신경 줄기 세포 |
| CN103305466B (zh) * | 2013-06-09 | 2015-02-11 | 吉林省拓华生物科技有限公司 | 一种保持高细胞活率的神经干细胞的培养方法 |
| ES2972541T3 (es) * | 2014-09-08 | 2024-06-13 | Riken | Método para producir tejido progenitor cerebeloso |
| CN104673752A (zh) * | 2015-03-14 | 2015-06-03 | 李�根 | 一种人脑干细胞库构建方法 |
| WO2018107135A1 (en) * | 2016-12-09 | 2018-06-14 | Neoneuron Llc | Method of treating neurological disorders with stem cell therapy |
| CN106924286A (zh) * | 2017-02-16 | 2017-07-07 | 上海安集协康生物技术股份有限公司 | 一种经鼻腔给药用于帕金森病治疗的神经干细胞制剂 |
| JP2024523361A (ja) | 2021-06-17 | 2024-06-28 | キュー－ステート バイオサイエンシーズ， インコーポレイテッド | 神経細胞を生産するための方法 |
| EP4355862A4 (en) * | 2021-06-18 | 2025-08-06 | Texas A & M Univ Sys | METHODS OF PROCESSING ADULT NEURAL CELLS FROM MAMMALS AND THEIR DOSAGES |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981165A (en) * | 1991-07-08 | 1999-11-09 | Neurospheres Holdings Ltd. | In vitro induction of dopaminergic cells |
| CA2403000C (en) * | 2000-03-14 | 2015-06-23 | Es Cell International Pte Ltd | Embryonic stem cells and neural progenitor cells derived therefrom |
| WO2004081172A2 (en) * | 2003-03-12 | 2004-09-23 | Reliance Life Sciences Pvt. Ltd. | Derivation of terminally differentiated dopaminergic neurons from human embryonic stem cells |
-
2003
- 2003-06-23 EP EP03738499A patent/EP1516926A4/en not_active Withdrawn
- 2003-06-23 AU AU2003246176A patent/AU2003246176B2/en not_active Ceased
- 2003-06-23 CN CN038149354A patent/CN1662645B/zh not_active Expired - Fee Related
- 2003-06-23 IL IL16577203A patent/IL165772A0/xx unknown
- 2003-06-23 WO PCT/JP2003/007906 patent/WO2004007700A1/ja not_active Ceased
- 2003-06-23 US US10/518,749 patent/US8492145B2/en not_active Expired - Fee Related
- 2003-06-23 JP JP2004521136A patent/JP4439396B2/ja not_active Expired - Fee Related
- 2003-06-23 CA CA2489206A patent/CA2489206C/en not_active Expired - Fee Related
- 2003-06-23 KR KR1020047021075A patent/KR100846643B1/ko not_active Expired - Fee Related
- 2003-06-24 TW TW092117117A patent/TW200411058A/zh not_active IP Right Cessation
-
2004
- 2004-12-14 IL IL165772A patent/IL165772A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL165772A (en) | 2012-05-31 |
| TWI309678B (https=) | 2009-05-11 |
| CN1662645A (zh) | 2005-08-31 |
| AU2003246176A1 (en) | 2004-02-02 |
| JPWO2004007700A1 (ja) | 2005-11-10 |
| US8492145B2 (en) | 2013-07-23 |
| CN1662645B (zh) | 2013-06-12 |
| WO2004007700A1 (ja) | 2004-01-22 |
| US20050221479A1 (en) | 2005-10-06 |
| CA2489206C (en) | 2012-08-07 |
| KR20050016636A (ko) | 2005-02-21 |
| JP4439396B2 (ja) | 2010-03-24 |
| HK1079812A1 (en) | 2006-04-13 |
| CA2489206A1 (en) | 2004-01-22 |
| EP1516926A4 (en) | 2006-10-11 |
| KR100846643B1 (ko) | 2008-07-16 |
| IL165772A0 (en) | 2006-01-15 |
| EP1516926A1 (en) | 2005-03-23 |
| AU2003246176B2 (en) | 2006-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11406670B2 (en) | Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the CNS | |
| TW200411058A (en) | Process for producing nerve cells | |
| JP6644277B2 (ja) | 神経前駆細胞の集団 | |
| JP2022078245A (ja) | 多能性細胞を分化させるための方法 | |
| JP2001526884A (ja) | 神経前駆細胞、その製造方法および神経性欠陥治療におけるその使用 | |
| CN113528442A (zh) | 用于植入的中脑多巴胺（da）神经元 | |
| CN115968401A (zh) | 将干细胞分化为多巴胺能祖细胞的方法 | |
| JP2014509192A (ja) | 患者特異的な多分化能ニューロン幹細胞を生成する方法および組成物 | |
| KR20230165846A (ko) | 도파민성 전구세포 및 사용 방법 | |
| JP2004511266A (ja) | 間葉間質細胞に対する治療的利用法 | |
| JP4576545B2 (ja) | 羊膜由来因子による胚性幹細胞の培養方法 | |
| KR102141537B1 (ko) | 신경 줄기세포의 구형배양 방법 | |
| WO2010059738A1 (en) | Differentiation of stem cells into dopaminergic cells | |
| HK40105534A (zh) | 多巴胺能前体细胞及使用方法 | |
| HK1079812B (en) | Process for producing nerve cells | |
| HK1131640A (en) | Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns | |
| HK1131640B (en) | Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |